Using AH1-derived SPSYVYHQF/H-2Ld tetramers, we determined the relative number of CT26-specific CD8+ T cells in the blood of CT26 tumor-bearing mice from the various treatment cohorts in our high-dose study (figure 4A). This evidence concerns the gene CD8A and neoplasm.